Related references
Note: Only part of the references are listed.A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
Amer M. Zeidan et al.
BLOOD ADVANCES (2022)
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Courtney D. DiNardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Maximilian Stahl et al.
BLOOD ADVANCES (2021)
A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia
Benjamin K. Tomlinson et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Naval Daver et al.
CANCER DISCOVERY (2019)
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study
Guillermo Garcia-Manero et al.
BLOOD ADVANCES (2019)
A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients
Brenda W. Cooper et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial
Jie Jin et al.
LANCET ONCOLOGY (2013)
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
Alfonso Quintas-Cardama et al.
CANCER (2007)
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase
S O'Brien et al.
CANCER (2003)
Simultaneous homoharringtonine and interferon-α in the treatment of patients with chronic-phase chronic myelogenous leukemia
S O'Brien et al.
CANCER (2002)
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
HM Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
